only with


Indoco Remedies Ltd.
Indoco Remedies
Indoco Remedies Ltd. live price is ₹ 0.00. Price change 0.00, 0.00 percent.
₹ 0.00
0.00 (0.00)%
Healthcare
Small-cap - With a market cap of ₹21.05 Cr.
| EX-Date | Purpose |
|---|---|
| 11 08 2021 | Quarterly Results |
| 02 11 2021 | Quarterly Results |
| 01 02 2022 | Quarterly Results |
| 17 05 2022 | Audited Results & Final Dividend |
| 09 08 2022 | Quarterly Results |
| 10 11 2022 | Quarterly Results |
| 24 01 2023 | Quarterly Results |
| 23 05 2023 | Final Dividend & Audited Results |
| 25 07 2023 | Quarterly Results |
| 19 10 2023 | Quarterly Results |
| 23 01 2024 | Quarterly Results |
| 24 10 2024 | Quarterly Results |
| 21 01 2025 | Quarterly Results |
| 22 05 2025 | Final Dividend & Audited Results |
| 24 07 2025 | Quarterly Results |
| 06 11 2025 | Quarterly Results |
| 03 02 2026 | Quarterly Results |
| 07 05 2026 | Audited Results & Final Dividend |
| 28 07 2026 | Quarterly Results |
News
Indoco Remedies gets EU GMP certification for OSD facility in Himachal Pradesh
The inspection was carried out from April 22, 2026, to April 27, 2026
Indoco Remedies clears Malta Medicines Authority audit at Baddi facility
The facility has received EU GMP certification from the Malta Medicines Authority
USFDA concludes inspection of Indoco Remedies’ testing facility with zero observation
The inspection was carried out from April 08, 2026 to April 10, 2026
Indoco Remedies secures final ANDA approval for Brivaracetam Oral Solution from USFDA
Brivaracetam Oral Solution will be manufactured by the company at its manufacturing facility located at Verna, Goa.
Indoco Remedies gets nod for Lacosamide Oral Solution
Lacosamide Oral Solution USP, will be manufactured by Indoco Remedies, at their manufacturing facility located at L-14, Verna Industrial Area, Verna, Goa
Indoco Remedies gets EIR from USFDA for API manufacturing facility at Patalganga
The inspection was conducted from September 15, 2025, to September 19, 2025.
USFDA completes inspection at Indoco Remedies’ API manufacturing facility
The inspection concluded with zero form 483 observations
Indoco Remedies gets final nod for Rivaroxaban Tablets
Rivaroxaban is used for the treatment of venous thromboembolism
Indoco Remedies gets Certificate of EU GMP Compliance for sterile drug product manufacturing facility in Goa
The company remains fully committed to adhering to cGMP standards and consistently delivering quality products to customers and patients worldwide
Indoco Remedies’ arm launches Ticagrelor film-coated tablets in UK
Ticagrelor film-coated tablets are indicated to reduce the chances of heart attack, stroke, myocardial infarction (MI) or diseases related to the heart or blood vessels
Indoco Remedies gets USFDA’s final approval for Allopurinol Tablets
This product, Allopurinol Tablets USP 200 mg, will be manufactured by Indoco Remedies at their manufacturing facility located at Verna, Goa
Indoco Remedies’ AnaCipher completes 5-day comprehensive USFDA inspection
The facility received 1 Form 483 at the end of the inspection, which will be responded within timeframe
Indoco Remedies gets warning letter for Goa facility
Earlier, the company had received Official Action Indicated status from USFDA for said facility
Indoco Remedies enters into strategic distribution partnership with Clarity Pharma, UK
Clarity Pharma has over 25 years of experience in bringing products to market and now services over 4,000 Primary Healthcare customers
Indoco Remedies gets final ANDA approval from USFDA for Varenicline Tablets
Varenicline is used to aid smoking cessation treatment
Indoco Remedies gets USFDA’s approval for Cetirizine Hydrochloride Tablets
Cetirizine Hydrochloride Tablets USP, 10 mg will be manufactured by the company, at their manufacturing facility located at Goa
Indoco Remedies’ arm commences commercial production of Pharmaceutical Intermediates
Warren Remedies has commenced its commercial production on March 24, 2024 from its Greenfield manufacturing facility located at Aurangabad
Indoco Remedies gets nod to purchase land in Mumbai
The Committee of Executive Directors at its meeting held on March 12, 2024 has approved the same
Indoco Remedies’ arm starts commercial production of oral care products
Warren Remedies has commenced its commercial production on March 1, 2024
Indoco Remedies gets EIR for Goa manufacturing facility from USFDA
The receipt of the Establishment Inspection Report indicates a successful closure of the inspection
Indoco Remedies receives USFDA’s approval for Canagliflozin Tablets
Canagliflozin improves glycemic control in adults with type 2 diabetes mellitus
Indoco Remedies gets EU GMP certification for Baddi manufacturing site
The EU GMP certification will support supplies of drug products to Europe and other territories from this manufacturing site
Indoco Remedies reports 37% fall in Q1 consolidated net profit
Total consolidated income of the company increased by 4.29% at Rs 426.91 crore for Q1FY24
Indoco Remedies gets EU GMP certification for Goa manufacturing site
The company has received EU GMP certification from the Competent Health Authority of Germany
Indoco Remedies gets EU GMP certification for Baddi facility
The EU GMP certification issued by the German Health Authority
Indoco Remedies acquires 85% stake in FPP Holding Company
The strategic investment by Indoco marks a significant milestone, solidifying its position as a key player in the US market
USFDA issues 4 observations to Indoco Remedies’ Sterile facility at Goa
USFDA had inspected the said facility from February 20, 2023 to February 28, 2023
Indoco Remedies reports 36% fall in Q4 consolidated net profit
Total consolidated income of the company increased by 4.70% at Rs 428.66 crore for Q4FY23
Indoco Remedies gets EIR from USFDA for manufacturing facility in Goa
The company has received EIR with Voluntary Action Indicated status from USFDA
USFDA conducts GMP inspection at Indoco Remedies’ Goa Facility
The inspection was conducted from February 20, 2023 to February 28, 2023
Indoco Remedies reports 15% drop in Q3 consolidated net profit
Total consolidated income of the company increased by 11.56% to Rs 399.56 crore for Q3FY23
USFDA conducts GMP inspection at Indoco Remedies’ Solid Oral Formulation Facility in Goa
The inspection was conducted from January 16, 2023 to January 20, 2023
Indoco Remedies’ AnaCipher CRO clears USFDA inspection with Zero 483s
This is the seventh successive USFDA inspection with ZERO 483s for AnaCipher CRO
Indoco Remedies to acquire stake in Kanakal Wind Energy
Post-acquisition Kanakal Wind Energy will be associate of Indoco Remedies
Indoco Remedies to acquire up to 26% stake in Jalansar Wind Energy
The purpose of entering into the Agreements is to establish the Solar Power Plant at Akkalkot
USFDA concludes inspection at Indoco Remedies’ Clinical Research Organization
This inspection was conducted by the Division of New Drug Study Integrity, Office of Study Integrity and Surveillance of USFDA
Indoco Remedies incorporates wholly owned subsidiary company
Cost of acquisition is Rs 1 lakh

